Other substances

Peramivir

An anti-influenza A/B drug.

Phase of research

Potential treatment - theoretical effect

How it helps

Antiviral

Drug status

Used to treat other disease

1
 Supporting references
0
 Contradictory references
3
 AI-suggested references
0
 Clinical trials

General information

Peramivir on PubChem

Marketed as

PERAMIFLU; RAPIACTA; RAPIVAB

 

Structure image - Peramivir

CCC(CC)[C@@H]([C@H]1[C@@H](C[C@@H]([C@H]1O)C(=O)O)N=C(N)N)NC(=O)C

Supporting references

Link Tested on Impact factor Notes Publication date
MCCS: a novel recognition pattern-based method for fast track discovery of anti-SARS-CoV-2 drugs
3CLpro Small molecule In silico 		in silico 8.99

Predicted to inhibit the SARS-CoV-2 3C-like protease.

 Oct/20/2020

AI-suggested references

Link Publication date
Quantitative structure-activity relationships, molecular docking and molecular dynamics simulations reveal drug repurposing candidates as potent SARS-CoV-2 main protease inhibitors.
Jan/19/2022
Peramivir, an Anti-Influenza Virus Drug, Exhibits Potential Anti-Cytokine Storm Effects
Feb/28/2022
Comparison of Antiviral Agents for Seasonal Influenza Outcomes in Healthy Adults and Children
Aug/02/2021
Export (.csv)